The role of molecular or cytogenetic response as a favorable prognostic factor before hematopoietic stem cell transplantation for chronic myeloid leukemia

The discovery of tyrosine kinase inhibitors (TKIs) in the late 1990s revolutionized the treatment of patients with chronic myeloid leukemia (CML)1,2. Following the emergence of new TKIs, more recent studies have shown a life expectancy similar to that of the general population, making it possible to discontinue medication to reach the new milestone of treatment-free remission3,4. However, resistance to imatinib can occur in 10-15% of patients on first-line treatment and in approximately 10% of those on second-generation inhibitors5.

Source: Biology of Blood and Marrow Transplantation - March 22, 2024 Category: Hematology Authors: Giuliana Rosendo de Oliveira Medeiros, Vaneuza Ara újo Moreira Funke, Alberto Cardoso Martins Lima, Ana Lúcia Vieira Mion, Isabela Menezes, Daniela Carinhanha Setubal, Caroline Bonamin dos Santos Sola, Gláucia Tagliari, Rafael Marchesini, Samir Kanaan Source Type: research